Else Nutrition Receives Key U.S. Patent Notice of Allowance for Use in Functional Food
08 Octobre 2021 - 1:00PM
ELSE NUTRITION HOLDINGS INC.
(BABY.V)
(BABYF)
(0YL.F) ("Else" or the
"Company") the Plant-Based baby, toddler and
children nutrition company, announces that it has just received a
U.S. Notice of Allowance on the composition of its proprietary
formulation, for use in functional food.
The Company already holds a worldwide patent
covering its Plant-Based Toddler and Infant formulas, and
supplemental nutrition for adults including patents for the
composition which provides the necessary proteins, amino-acids and
other nutrients needed in a single food serving.
“This development is of monumental importance;
it paves the way for future planned product expansion beyond the
baby, toddler and kids’ markets,” stated Hamutal Yitzhak, CEO and
Co-Founder of Else Nutrition. “Our 100% Plant-Based solution has
functional and meaningful applications to a wide range of potential
consumer markets. While we remain laser-focused on the launch of
our baby products, our IP can also help serve the rapidly growing
$5 billion U.S. Plant-Based food market, giving those in need,
nutritious functional wholefood clean label offerings,” she
added.
The Notice of Allowance indicates that the U.S Patent and
Trademark Office (USPTO) has decided to issue the requested
patent.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food
and nutrition company focused on developing innovative, clean and
plant-based food and nutrition products for infants, toddlers,
children, and adults. Its revolutionary, plant-based, non-soy,
formula is a clean-ingredient alternative to dairy-based formula.
Else Nutrition (formerly INDI) won the "2017 Best Health and Diet
Solutions" award at the Global Food Innovation Summit in Milan.
Else Plant-Based Complete Nutrition for Toddlers was recently
ranked as the #1 Top seller in the baby and toddler formula
category on Amazon. The holding company, Else Nutrition Holdings
Inc., is a publicly traded company, listed as TSX Venture Exchange
under the trading symbol BABY and is quoted on the US OTC Markets
QX board under the trading symbol BABYF and on the Frankfurt
Exchange under the symbol 0YL. Else's Executives includes
leaders hailing from leading infant nutrition companies. Many
of Else advisory board members had past executive roles in
companies such as Mead Johnson, Abbott Nutrition, Plum Organics and
leading infant nutrition Societies, and some of them
currently serve in different roles in leading medical centers and
academic institutes such as Boston Children's Hospital, Pediatrics
at Harvard Medical School, USA, Tel Aviv University, Schneider
Children's Medical Center of Israel, Rambam Medical Center and
Technion, Israel and University Hospital Brussels, Belgium.
For more information,
visit: elsenutrition.com or @elsenutrition on Facebook
and Instagram.
Media ContactCallie RappBrilliant
PRcallier@brilliantpr.com
For more information, contact:Mrs. Hamutal
Yitzhak, CEO, Co-Founder & DirectorELSE Nutrition Holdings
Inc.E: hamutaly@elsenutrition.comP: +972(0)3-6445095
Mr. Sokhie Puar, Director of Else
NutritionE: sokhiep@elsenutrition.comP: 604-603-7787
TSX Venture Exchange
Neither the TSX Venture Exchange nor its
regulation services provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Caution Regarding Forward-Looking
Statements
This press release contains statements that may
constitute “forward-looking statements” within the meaning of
applicable securities legislation. Forward-looking statements are
typically identified by words such as “will” or similar
expressions. Forward-looking statements in this press release
include statements with respect to the anticipated dates for filing
the Company’s financial disclosure documents. Such
forward-looking statements reflect current estimates, beliefs and
assumptions, which are based on management’s perception of current
conditions and expected future developments, as well as other
factors management believes are appropriate in the circumstances.
No assurance can be given that the foregoing will prove to be
correct. Forward-looking statements made in this press release
assume, among others, the expectation that there will be no
interruptions or supply chain failures as a result of COVID 19 and
that the manufacturing, broker and supply logistic agreement with
the Company do not terminate. Actual results may differ from the
estimates, beliefs and assumptions expressed or implied in the
forward-looking statements. Readers are cautioned not to place
undue reliance on any forward-looking statements, which reflect
management’s expectations only as of the date of this press
release. The Company disclaims any obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
Else Nutrition (TSXV:BABY)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Else Nutrition (TSXV:BABY)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024